Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Telix Pharmaceuticals
Biotech
Telix shows 'promising’ 13-month OS in ph. 2 brain cancer study
Telix Pharmaceuticals has pointed to “promising efficacy” for its radiation therapy in a small study of patients with brain cancer.
James Waldron
Apr 16, 2025 6:30am
J&J innovator vaults to Valo—Chutes & Ladders
Apr 11, 2025 8:30am
Telix pays $45M for ImaginAb's preclinical antibodies, facility
Jan 13, 2025 7:50am
Cell-focused Sana scoops first CSO—Chutes & Ladders
Aug 30, 2024 8:30am
Radiopharma biotech Telix drops Nasdaq IPO plans at last minute
Jun 14, 2024 5:37am
Radiopharma-focused Telix targets $200M IPO
Jun 5, 2024 10:57am
